Does HRT Help Lichen Sclerosus? What Guidelines and Studies Say

Does HRT help lichen sclerosus? Not as a treatment for the condition itself. The 2024 European dermatology guideline recommends against using estrogen on the vulva to treat lichen sclerosus, and the treatment it recommends is a strong steroid ointment. But if you also have menopause-related vaginal dryness, vaginal estrogen may help with that separate problem.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

What we actually verified · Last verified October 2026

• What we read: the 2024 EuroGuiDerm guideline on lichen sclerosus (Journal of the European Academy of Dermatology and Venereology), The Menopause Society's 2020 position statement on genitourinary syndrome of menopause and its 2022 hormone therapy position statement, a 2023 review in Frontiers in Medicine, a 2020 American Family Physician review of chronic vulvar conditions, the NHS and British Association of Dermatologists patient pages, PubMed abstracts of the main cancer-risk and treatment studies, a 2023 case report on lichen sclerosus with coexisting genitourinary syndrome, and the FDA labels for an estradiol vaginal cream, a systemic estradiol patch and a clobetasol ointment. Every source is listed at the bottom with the date we read it.
• What we did not do: we did not examine anyone, review anyone's biopsy or records, or speak with a clinician for this page. This is editorial research, not medical review, and not advice for your situation.
• Commercial interest: The HRT Index may earn a commission from some providers featured through The HRT Index's Find My HRT Path tool. No provider paid for this page, and no provider reviewed it. See our affiliate disclosure.
• Verification Standard: we judge online menopause care on five pillars, in this order: clinical legitimacy, care quality, medication fit, price transparency and access. Our methodology explains how.

Jump to: Quick answer by situation · Lichen sclerosus vs. menopause dryness · What the research says about estrogen · Where vaginal estrogen can help · What actually treats it · Cancer risk and follow-up · In person first · Questions to ask · Online care · FAQ · Sources

Does HRT help lichen sclerosus? A quick answer for your situation

Lichen sclerosus (LS) and menopause can show up at the same time, in the same place, with some of the same symptoms. That's why the question comes up so often. The short version is that hormones and LS treatment do different jobs. Here is how the evidence we read applies to common situations.

The right online menopause care isn't the same for every woman — it depends on your symptoms, what you've already tried, your age, your state and your health history. Some situations belong with an in-person clinician first. Use The HRT Index's Find My HRT Path tool to explore a featured care option for your situation — and to flag when online care isn't the right starting point — before your first consult.

Find My HRT Path is free, takes about 60 seconds and doesn't ask for your email. It asks about your symptoms (one option is "Vaginal dryness or painful sex"), what you've tried, your age, your state and your health history. Then it shows a featured care option or flags when in-person care makes more sense. It is not a diagnosis, and it does not decide whether you should be prescribed anything.

What is lichen sclerosus, and how is it different from menopause dryness?

Lichen sclerosus is a long-term inflammatory skin condition that mostly affects the genital and anal skin. A 2023 review in Frontiers in Medicine calls it "underdiagnosed." It says postmenopausal women are the group most affected, with smaller numbers of men, children and teenagers. The same review describes two age peaks in women: one before puberty (average age 7.6) and one around peri- and postmenopause (average age 52.6).

The NHS says LS is "much more common in women over 50." The American Family Physician review puts its prevalence at about 1.7% in general gynecology practice. LS isn't an infection and isn't contagious, according to the British Association of Dermatologists (BAD).

Genitourinary syndrome of menopause (GSM) is the newer name for vaginal atrophy. It's the set of vulvar, vaginal and urinary changes that come from falling estrogen. The American Family Physician review says about half of women develop GSM symptoms within three years of menopause. A 2023 case report in the International Journal of Women's Dermatology cites estimates that GSM affects between 13% and 87% of postmenopausal women.

Because both conditions are common at the same age, many women have both. The European guideline says estrogen loss "is independent from vulval changes of LS, although both conditions may occur simultaneously." Telling them apart matters, because they're treated differently.

Lichen sclerosus vs. genitourinary syndrome of menopause

This comparison pulls together the descriptions in the sources listed below. It's meant to help you talk to a clinician, not to diagnose yourself. Only an examination, and sometimes a biopsy, can do that.

One clue clinicians use is timing. The Menopause Society's 2020 GSM position statement lists lichen sclerosus among the conditions that can look like GSM. It says another cause "is more likely in women with chronic or recurrent vulvovaginal symptoms that were present before menopause." It also says a culture or biopsy "should be considered" if findings look unusual or if symptoms "fail to resolve after a trial of vaginal estrogens or DHEA."

In plain terms, if vaginal estrogen hasn't fixed your itching or soreness, that's a reason to get re-examined, not just to use more estrogen. Our guide to vaginal dryness that isn't improving on HRT walks through other causes. If itching is your main symptom, our page on menopause and itching covers the wider list of possibilities.

What does the research say about estrogen and lichen sclerosus?

If LS peaks around menopause, it seems logical that replacing estrogen would treat it. That theory has been tested, and it hasn't held up.

The 2024 European guideline: a clear recommendation against

The EuroGuiDerm guideline on lichen sclerosus was published in 2024 in the Journal of the European Academy of Dermatology and Venereology. It's the most detailed recent guideline we found. Its recommendation, passed with 100% agreement from the expert panel, reads:

"We recommend against topical oestrogen on the vulva in women as a treatment for genital lichen sclerosus. However, women may have additional genitourinary syndrome in which topical vaginal oestrogens may be helpful."

The guideline gives several reasons. It notes that "the vulva itself has few oestrogen receptors." It also concludes that "topical oestrogens for the treatment of LS alone cannot be recommended, even though published data of comparative trials are not available." That last point matters: there's no head-to-head trial of estrogen against steroids for LS. The recommendation rests on how the disease behaves and on expert consensus, not on a trial showing harm.

The same guideline also recommends against topical testosterone and topical progesterone for LS, and against topical hormone products in girls with LS.

Other evidence points the same way

The Menopause Society's GSM statement adds one more data point: topical testosterone has been used for LS "despite limited efficacy data."

What this means for you: We found no guideline that recommends HRT (vaginal or systemic) as a treatment for lichen sclerosus. Studying the link between HRT and LS risk is a reasonable research question, but one small observational study isn't a basis for treatment.

Where vaginal estrogen can help when you have lichen sclerosus

This is the part of the answer that often gets lost. HRT doesn't treat LS, but many women with LS are also postmenopausal and have GSM. If you only treat the LS, the GSM symptoms can stay.

The European guideline says vaginal estrogen "might be of advantage for sexually active postmenopausal women with LS due to its lubrication effect, to avoid soreness and tearing after intercourse." Notice the wording: it's about vaginal estrogen and the vaginal tissue, as an add-on. It is not about estrogen replacing LS treatment.

A 2023 case report in the International Journal of Women's Dermatology (Desai and Corley) describes this exact situation. A 60-year-old woman had biopsy-proven LS that was controlled on a strong steroid ointment, but her burning continued. She was found to have GSM as well and was given estradiol cream, and her symptoms resolved at three months. The authors write: "If LS is treated without addressing co-existence of GSM, this may lead to ongoing patient discomfort despite clinical control of LS." This is one patient, so it shows what's possible, not what's likely. It does match what the guideline describes.

What the menopause guidelines say about low-dose vaginal estrogen

• The Menopause Society's 2022 hormone therapy position statement says low-dose vaginal estrogen is effective, generally safe and has minimal absorption into the bloodstream. It is the preferred hormone option when genitourinary symptoms are the only symptoms.
• The same statement says a progestogen generally isn't needed with low-dose vaginal estrogen, though it notes that trial data beyond one year are lacking. Our page on whether you need progesterone with vaginal estrogen covers this in more detail.
• The American Family Physician review lists moisturizers, lubricants and avoiding irritants as first-line GSM care, followed by low-dose vaginal estrogen.
• Women with a history of breast cancer should discuss vaginal estrogen with their oncologist, per the 2022 statement. See vaginal estrogen after breast cancer.

What the label says

The FDA label for Estrace (estradiol vaginal cream) lists its use as treating "moderate to severe symptoms of vulvar and vaginal atrophy due to menopause." Lichen sclerosus isn't listed. If a clinician prescribes vaginal estrogen when you have LS, the usual reason is coexisting atrophy (GSM), not the LS itself.

The label's contraindications include undiagnosed abnormal genital bleeding, known or suspected breast cancer, estrogen-dependent cancers, past or current blood clots in the legs or lungs, arterial clotting disease such as stroke or heart attack, and liver disease, among others. Our page on who should not take HRT covers these lists, and vaginal estrogen side effects covers what to expect.

If vaginal estrogen isn't right for you, there are non-estrogen GSM options. See our pages on non-estrogen treatment for vaginal dryness, vaginal DHEA vs. estrogen and ospemifene vs. vaginal estrogen. None of them is a treatment for LS either.

What actually treats lichen sclerosus?

Every guideline and patient resource we read agrees on the first-line treatment: a very strong steroid ointment applied to the affected skin.

Ultrapotent steroid ointment

• The standard choice: The European guideline calls ultrapotent or potent topical steroids the "gold standard." It reports that about 60–70% of patients have complete symptom remission after a three-month course of clobetasol propionate 0.05%. Mometasone furoate 0.1% performed similarly in a comparison it cites. The Frontiers review says clobetasol improves symptoms and signs in about three-quarters of women with vulvar LS.
• Ointment rather than cream: The European guideline prefers ointments to creams, and it recommends using an emollient (a plain moisturizing ointment or soap substitute) alongside.
• How much: The guideline says one fingertip unit (the amount squeezed along the tip of an adult finger) is enough to cover the whole vulva.
• How often: Schedules differ. The BAD patient leaflet describes a common UK schedule of daily use for the first month, alternate days in the second month and twice a week in the third, and the European and US sources describe their own variations. Your clinician sets your schedule. Don't change it based on a website, this one included.
• Long-term use: LS often comes back, so many people stay on a maintenance schedule. The European guideline says long-term treatment "is thought to prevent architectural changes and carcinoma development." It says the steroids "can be applied in LS over years without significant clinically relevant adverse effects."

Why your clobetasol tube says "not for the groin"

This confuses a lot of people. The FDA label we read for clobetasol propionate 0.05% ointment says treatment "beyond 2 consecutive weeks is not recommended." It says the ointment "should not be used on the face, groin, or axillae." It also says use in children under 12 isn't recommended.

Guidelines for LS recommend longer use on the vulva under a clinician's supervision, which counts as off-label use of the label's general directions. The BAD leaflet addresses this directly: it tells patients not to worry about the warning on the packaging about using it on genital skin, because it's safe when used as directed for LS. If the label and your prescription instructions seem to disagree, ask your prescriber, and don't simply stop treatment.

What the evidence says about sticking with treatment

A 2015 study in JAMA Dermatology (Lee et al.) followed 507 women with biopsy-proven vulvar LS. Among women who used their steroid treatment consistently, none developed vulvar cancer or precancer (VIN) during follow-up. Among women who used it only partly, 7 (4.7%) did. Symptom control was 93.3% versus 58.0%, and scarring was 3.4% versus 40.0%. Steroid-related skin thinning was uncommon in both groups (1.1% and 2.0%). This is an observational study, so it can't prove the steroid caused the difference, but it's a strong reason not to stop treatment when symptoms ease.

Second-line and other options

Cancer risk and follow-up

LS raises the risk of vulvar squamous cell carcinoma (SCC). The risk for any one person is still low, but it's the main reason LS needs ongoing medical follow-up, and why "just trying HRT" isn't a substitute for proper care.

Follow-up schedules differ (every six months in the US review, yearly in the European guideline), so follow the schedule your clinician gives you.

The NHS and BAD both tell patients to watch for a lump, a thickened area, or an ulcer or sore that doesn't heal, and to get it checked. Don't treat a new change like that at home with estrogen or anything else.

When to see a clinician in person first

Online menopause care is built around conversation, history and prescriptions. LS is a condition that clinicians need to see, and sometimes biopsy. These situations call for an in-person visit before anything else:

• You have vulvar itching, white patches, skin that bleeds or hurts easily, or changes in shape, and no diagnosis. LS needs an examination. The US review says a definitive diagnosis should be made with a biopsy. European guidance says an experienced clinician can often diagnose it by looking, with a biopsy when there's doubt.
• You notice a lump, a thickened or raised area, or a sore that won't heal. This is the warning sign named in patient guidance.
• You've used vaginal estrogen and your itch or soreness hasn't cleared. The Menopause Society statement says this is a reason to consider a biopsy or culture.
• You have bleeding you can't explain. Undiagnosed genital bleeding is a contraindication on the estradiol label we read, and it needs its own evaluation.
• You have pain passing urine or opening your bowels, or narrowing that makes sex or exams impossible. Scarring needs specialist assessment.
• The patient is a child. The BAD leaflet says all children with LS should see a specialist, and that childhood LS often settles around puberty but may come back. The Estrace label says it is "not indicated in children," and the European guideline recommends against topical hormone products in girls.
• You have a history of breast cancer, a blood clot, stroke, heart disease or liver disease. These come up in estrogen decisions, so plan them with your oncologist or a clinician who knows your full history.

The NHS also lists simple self-care steps for LS, including using an emollient instead of soap, wearing cotton underwear and using a lubricant for sex. These support treatment but don't replace it.

Questions to ask your clinician

Bring these to your gynecologist, dermatologist or menopause clinician:

1. "Is this lichen sclerosus, GSM, or both? Do I need a biopsy to be sure?"
2. "What steroid ointment, how much, and on what schedule? What should my maintenance plan look like?"
3. "My tube says not to use it on the groin or for more than two weeks. How does that fit with your instructions?"
4. "If my LS is controlled but I still have dryness or pain with sex, could vaginal estrogen help? Or would a non-estrogen option fit better?"
5. "Do I need a progestogen with the vaginal estrogen you're suggesting?"
6. "Is systemic HRT reasonable for my hot flashes or sleep, given my LS and my health history?"
7. "How often should I be checked, who will do it, and what changes should make me book sooner?"
8. "Are there other autoimmune conditions I should be screened for?"

Can online menopause care help if you have lichen sclerosus?

Online care can be part of the picture, but not all of it. Here is how our five pillars apply to LS:

• Clinical legitimacy: A licensed clinician should be clear about what they can't do on video. A responsible online service shouldn't diagnose or manage LS without an in-person exam, and it should ask whether you've been diagnosed. Our page on whether online HRT is safe covers the warning signs.
• Care quality: If you have LS and want help with GSM or hot flashes, good care means the clinician asks about your LS diagnosis, your current steroid plan and who's following you for cancer checks. It also means they don't stop or replace that treatment.
• Medication fit: Vaginal estrogen for coexisting GSM and systemic HRT for menopause symptoms are the kinds of treatment online menopause care focuses on. Neither replaces your LS ointment. Our page on vaginal estrogen vs. systemic estrogen explains the difference.
• Price transparency: Check what visits, medication and follow-ups cost before you start. LS follow-up with your in-person clinician is a separate cost.
• Access: Online care can make it easier to get GSM or menopause treatment between in-person LS check-ups. Our page on vaginal estrogen without a pelvic exam covers when an exam matters. If you have LS, or symptoms that might be LS, you need that in-person exam anyway.

A reasonable order for many women is: get LS diagnosed and controlled in person, keep up the follow-up, and then look at whether online menopause care fits the other parts of menopause. Our guides to GSM treatment online, online treatment for vaginal atrophy and online care for painful sex compare the options.

Frequently asked questions

Does HRT help lichen sclerosus?

Not as a treatment for the condition itself. The 2024 European dermatology guideline recommends against estrogen on the vulva as an LS treatment, and no guideline we found recommends HRT for LS. The standard treatment is a very strong steroid ointment such as clobetasol. Vaginal estrogen may help coexisting menopause dryness (GSM).

Can estrogen cream make lichen sclerosus go away?

The evidence we read doesn't support that. The European guideline says topical estrogen for LS alone "cannot be recommended," and a 2023 review lists it as "not recommended." Estrogen cream can improve vaginal dryness from GSM, which can sit alongside LS. That may ease some discomfort without treating the LS.

Does menopause cause lichen sclerosus?

Not directly, as far as research can show. LS is most common after menopause, but it also occurs in young girls and in men. A 2023 review says the theory that low estrogen causes LS "could not be proved," and the British Association of Dermatologists says it isn't related to hormonal abnormalities.

Can I take systemic HRT if I have lichen sclerosus?

LS isn't on the contraindication lists in the estradiol labels we read. The decision depends on your other health history, such as breast cancer, blood clots, stroke or liver disease, so discuss it with a clinician. Systemic HRT doesn't replace your LS treatment or follow-up.

Can I use vaginal estrogen and clobetasol at the same time?

The European guideline says women with LS who also have GSM may benefit from vaginal estrogen, and a 2023 case report describes a woman using both. How to combine and time them is a question for your prescriber, so ask them directly.

Is lichen sclerosus cancer?

No. But it raises the risk of vulvar squamous cell carcinoma. Estimates in the sources we read are around 4–5% overall, and a Dutch cohort reported 6.7% cumulative incidence. A 2015 study found no cancers among women who used treatment consistently. Lifelong follow-up and getting new lumps or sores checked are the key steps.

Can lichen sclerosus be diagnosed online?

Online care isn't a good fit for diagnosing LS. It needs a clinician to examine the skin, and sometimes to take a biopsy. Once LS is diagnosed and being managed, online menopause care may help with other menopause symptoms.

The bottom line

HRT doesn't treat lichen sclerosus. The 2024 European guideline recommends against estrogen on the vulva for LS, and its recommended treatment is a strong steroid ointment, used long term under follow-up because of the small but real cancer risk. Where hormones can help is the separate, very common problem of menopause-related vaginal dryness. If your LS is controlled but sex or everyday comfort still hurts, ask about vaginal estrogen or a non-estrogen option for GSM.

If you're figuring out where menopause care fits alongside your in-person LS care, Find My HRT Path can help you see what fits and flag when in-person care should come first.

Related reading

• Menopause and itching: what's causing it
• Vaginal dryness not improving on HRT
• Vaginal estrogen: the complete guide
• How long does vaginal estrogen take to work?
• Is vaginal estrogen safe long term?
• How to use vaginal estrogen cream
• Can you take HRT with inflammatory bowel disease?

Sources

All sources were read on October 29, 2026.

1. Kirtschig G, et al. EuroGuiDerm Guideline on lichen sclerosus — treatment of lichen sclerosus. J Eur Acad Dermatol Venereol. 2024;38(10):1874–1909. https://pubmed.ncbi.nlm.nih.gov/38822598/
2. De Luca DA, et al. Lichen sclerosus: the 2023 update. Front Med. 2023;10:1106318. https://pubmed.ncbi.nlm.nih.gov/36873861/
3. Desai S, Corley SB. Treating co-existent genitourinary syndrome of menopause in patients with lichen sclerosus improves symptoms. Int J Womens Dermatol. 2023;9(1):e071. https://pubmed.ncbi.nlm.nih.gov/36700161/
4. Ringel NE, Iglesia C. Common benign chronic vulvar disorders. Am Fam Physician. 2020;102(9):550–557. https://www.aafp.org/pubs/afp/issues/2020/1101/p550.html
5. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976–992. https://pubmed.ncbi.nlm.nih.gov/32852449/
6. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–794. https://menopause.org/wp-content/uploads/professional/nams-2022-hormone-therapy-position-statement.pdf
7. NHS. Lichen sclerosus. https://www.nhs.uk/conditions/lichen-sclerosus/
8. British Association of Dermatologists. Lichen sclerosus in females (patient information leaflet). https://www.bad.org.uk/pils/lichen-sclerosus-in-females/
9. Lee A, Bradford J, Fischer G. Long-term management of adult vulvar lichen sclerosus: a prospective cohort study of 507 women. JAMA Dermatol. 2015;151(10):1061–1067. https://pubmed.ncbi.nlm.nih.gov/26070005/
10. Bleeker MC, et al. Lichen sclerosus: incidence and risk of vulvar squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2016;25(8):1224–1230. https://pubmed.ncbi.nlm.nih.gov/27257093/
11. Halonen P, et al. Lichen sclerosus and risk of cancer. Int J Cancer. 2017;140(9):1998–2002. https://pubmed.ncbi.nlm.nih.gov/28124469/
12. Halonen P, et al. Risk factors for lichen sclerosus: a case-control study of 43,000 Finnish women. J Low Genit Tract Dis. 2024;28(2):164–168. https://pubmed.ncbi.nlm.nih.gov/38518214/
13. Bracco GL, et al. Clinical and histologic effects of topical treatments of vulval lichen sclerosus. A critical evaluation. J Reprod Med. 1993;38(1):37–40. https://pubmed.ncbi.nlm.nih.gov/8441129/
14. Higgins CA, Cruickshank ME. A population-based case-control study of aetiological factors associated with vulval lichen sclerosus. J Obstet Gynaecol. 2012;32(3):271–275. https://pubmed.ncbi.nlm.nih.gov/22369403/
15. Estrace (estradiol vaginal cream) prescribing information. DailyMed, US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dfc41fcd-c5ba-4b25-b647-cf04d3988b3e
16. Clobetasol propionate ointment USP, 0.05% prescribing information. DailyMed, US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=60f65ee3-b972-4e58-97fe-0c0ab14b9b48
17. Climara (estradiol transdermal system) prescribing information. DailyMed, US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e9702c4-f2d7-4ea8-b6e8-7dca31671864

This page is for education only and is not medical advice. It doesn't replace an examination, diagnosis or treatment plan from a clinician who knows your health history. If you notice a new lump, a sore that won't heal or unexplained bleeding, see a clinician in person.